The role of minocycline in ischemia-reperfusion injury: A comprehensive review of an old drug with new implications

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 2, 2011, Pages 123-132

  Ulgen, Berkin O ^a   Field, Matthew G ^b   Qureshi, Waqas ^a   Knight, Richard A ^c   Stephanou, Anastasis ^c   Latchman, David S ^c   Vasquez, Diego ^a   Barry, Sean P ^c   Saravolatz II, Louis ^a   Scarabelli, Gabriele M ^a   Faggian, Giuseppe ^d   Mazzucco, Alessandro ^d   Saravolatz, Louis ^a   Carol Chen Scarabelli, ^e   Scarabelli, Tiziano M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Apoptosis; Ischemia reperfusion injury; Minocycline

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; METALLOPROTEINASE; MINOCYCLINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PENICILLIN G; PROCASPASE 9; PROTEIN BCL 2; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ACNE VULGARIS; AMEBIASIS; ANTHRAX; APOPTOSIS; BLOOD BRAIN BARRIER; CHLAMYDIA TRACHOMATIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; GASTROINTESTINAL IRRITATION; HUMAN; LIVER TOXICITY; MYCOBACTERIUM MARINUM; PERIODONTITIS; PRIORITY JOURNAL; REPERFUSION INJURY; RESPIRATORY TRACT INFECTION; REVIEW; SOFT TISSUE INFECTION; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; HUMANS; MINOCYCLINE; PATENTS AS TOPIC; REPERFUSION INJURY;

EID: 79959326926     PISSN: 15748901     EISSN: 15748901     Source Type: Journal    
DOI: 10.2174/157489011795933783     Document Type: Review

References (116)

1. Gallagher DJ, Settle KL. A new tetracycline minocycline compared with ampicillin in general practice. N Z Med J. 1976; 83(558): 105-7.
2. Triax. Minocin (minocycline hydrochloride) pellet-filled capsules prescribing information. In: Pharmaceuticals T, Editor. Cranford, NJ 2006.
3. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791(1-2): 337-43.
4. NC, Cunha BA. Tetracyclines. Med Clin North Am. 1995;79(4): 789-801.
5. McEvoy G. AHFS Drug information: Tetracycline general statement. Amer Soc Health-Sys Pharma 2004; 433-49.
6. Chambers HF. Tetracyclines. In: Laurence L Brunton JSL, Keith LP, Ed. Goodman and Gilman's the pharmacological basis of therapeutics 11. 11/e ed. New York: McGraw-Hill Company, Inc.2006.
7. Nelis HJ, De Leenheer AP. Evidence for metabolic inertness of doxycycline. J Pharm Sci 1981; 70(2): 226-8.
8. Bocker RH, Peter R, Machbert G, Bauer W. Identification and determination of the two principal metabolites of minocycline in humans. J Chromatogr. 1991; 568(2): 363-74.
9. Wyeth. Minocin (minocycline hydrochloride) pellet-filled capsules prescribing information. In: Wyeth, Ed. Philadelphia, PA 2005.
10. Medicis. Dynacin (minocycline HCL) capsules prescribing information. Scottsdale. 2004.
11. Watson. Minocycline hydrochloride capsules USP Prescribing Information. In: Watson, Ed. Corona, CA. 2005.
12. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, et al. Minocycline to improve neurologic outcome in stroke (MINOS): A dose-finding study. Stroke 2010; 41(10): 2283-7.
13. Sanchez AR, Rogers RS, 3rd, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 2004; 43(10): 709-15.
14. Brayton JJ, Yang Q, Nakkula RJ, Walters JD. An in vitro model of ciprofloxacin and minocycline transport by oral epithelial cells. J Periodontol 2002; 73(11): 1267-72.
15. Gabler WL. Fluxes and accumulation of tetracyclines by human blood cells. Res Commun Chem Pathol Pharmacol. 1991; 72(1): 39-51.
16. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79(4): 1431-568.
17. Louzada-Junior P, Dias JJ, Santos WF, Lachat JJ, Bradford HF, Coutinho-Netto J. Glutamate release in experimental ischaemia of the retina: an approach using microdialysis. J Neurochem. 1992; 59(1): 358-63.
18. Borutaite V, Brown GC. Mitochondria in apoptosis of ischemic heart. FEBS Lett 2003; 541(1-3):1-5.
19. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res 2004; 61(3): 372-85.
20. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68(2): 320-44.
21. Kumar C, Okuda M, Ikai I, Chance B. Luminol enhanced chemiluminescence of the perfused rat heart during ischemia and reperfusion. FEBS Lett 1990; 272(1-2): 121-4.
22. Murgia M, Giorgi C, Pinton P, Rizzuto R. Controlling metabolism and cell death: at the heart of mitochondrial calcium signalling. J Mol Cell Cardiol 2009; 46(6): 781-8.
23. Rodriguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev 2007; 12(3-4): 207-16.
24. Freude B, Masters TN, Robicsek F, Fokin A, Kostin S, Zimmermann R, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 2000; 32(2): 197-208.
25. Gottlieb RA, Engler RL. Apoptosis in myocardial ischemiareperfusion. Ann NY Acad Sci 1999; 874: 412-26.
26. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998; 97(3): 276-81.
27. Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T, et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998; 18(3): 238-47.
28. Bastos LF, Merlo LA, Rocha LT, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol 2007; 576(1-3): 171-9.
29. Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 2004; 43(5): 865-74.
30. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: Shedding new light on a shadowy controversy. Curr Drug Deliv. 2007; 4(3): 225-31.
31. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004; 9(1): 63-79.
32. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radicalscavenging activity. J Neurochem. 2005; 94(3): 819-27.
33. Huang WC, Qiao Y, Xu L, Kacimi R, Sun X, Giffard RG, et al. Direct protection of cultured neurons from ischemia-like injury by minocycline. Anat Cell Biol 2010;43(4): 325-31.
34. Corsani L, Bizzoco E, Pedata F, Gianfriddo M, Faussone-Pellegrini MS, Vannucchi MG. Inducible nitric oxide synthase appears and is co-expressed with the neuronal isoform in interneurons of the rat hippocampus after transient ischemia induced by middle cerebral artery occlusion. Exp Neurol 2008; 211(2): 433-40.
35. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001; 166(12): 7527-33.
36. Shi Y, Gaestel M. In the cellular garden of forking paths: How p38 MAPKs signal for downstream assistance. Biol Chem 2002; 383(10): 1519-36.
37. Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogenactivated protein kinases in microglia. Glia 2002; 40(2): 175-83.
38. Clark WM, Calcagno FA, Gabler WL, Smith JR, Coull BM. Reduction of central nervous system reperfusion injury in rabbits using doxycycline treatment. Stroke. 1994; 25(7): 1411-5; discussion 6.
39. Hua XY, Svensson CI, Matsui T, Fitzsimmons B, Yaksh TL, Webb M. Intrathecal minocycline attenuates peripheral inflammationinduced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci 2005; 22(10): 2431-40.
40. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006; 103(25): 9685-90.
41. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008; 5:15.
42. Attur MG, Patel RN, Patel PD, Abramson SB, Amin AR. Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. J Immunol 1999;162(6): 3160-7.
43. Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 2006; 96(2): 314-23.
44. Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44(6): 1165-70.
45. Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984; 120(10): 1308-13.
46. Thong YH, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol 1979; 35(3): 443-6.
47. Fernandez-Gomez FJ, Galindo MF, Gomez-Lazaro M, Gonzalez-Garcia C, Cena V, Aguirre N, et al. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 2005; 133(4): 959-67.
48. Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, et al. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 2004; 91(5): 1219-30.
49. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417(6884): 74-8.
50. Ca2+ entry in single nerve terminals. J Biol Chem 2002; 277(16): 14092-101.
51. Ca2+ signalling in hippocampal neurons. Eur J Neurosci 2007; 26(9): 2481-95.
52. Lee SM, Yune TY, Kim SJ, Kim YC, Oh YJ, Markelonis GJ, et al. Minocycline inhibits apoptotic cell death via attenuation of TNFalpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J Neurochem 2004; 91(3): 568-78.
53. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6(7): 797-801.
54. Wang J, Wei Q, Wang CY, Hill WD, HessDC, Dong Z. Minocycline up-regulates BCl-2 and protects against cell death in mitochondria. J Biol Chem. 2004; 279(19): 19948-54.
55. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312(3): 159-63.
56. Emonard H, Grimaud JA. Matrix metalloproteinases. A review. Cell Mol Biol 1990; 36(2): 131-53.
57. Bhatt LK, Addepalli V. Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res 2010; 2(2): 181-9.
58. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8(1): 82-9.
59. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152(2): 189-205.
60. Viappiani S, Sariahmetoglu M, Schulz R. The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver. Curr Pharm Des 2006; 12(23): 2923-34.
61. Soccal PM, Gasche Y, Miniati DN, Hoyt G, Berry GJ, Doyle RL, et al. Matrix metalloproteinase inhibition decreases ischemiareperfusion injury after lung transplantation. Am J Transplant 2004; 4(1): 41-50.
62. Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y, Geyer O. The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2007; 245(5): 725-32.
63. Roach DM, Fitridge RA, Laws PE, Millard SH, Varelias A, Cowled PA. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg 2002; 23(3): 260-9.
64. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004; 286(5): F893-902.
65. Holman BL, Idoine J, Fliegel CP, Davis MA, Treves S, Eldh P, et al. Detection and localization of experimental myocardial infarction with 99m Tc-tetracycline. J Nucl Med 1973; 14(8): 595-9.
66. Nelson ML. Chemical and biological dynamics of tetracyclines. Adv Dent Res 1998; 12(2): 5-11.
67. Tao R, Kim SH, Honbo N, Karliner JS, Alano CC. Minocycline protects cardiac myocytes against simulated simulated ischemiareperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 2010.
68. Hu X, Zhou X, He B, Xu C, Wu L, Cui B, et al. Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 2010; 638(1-3): 84-9.
69. Hu X, Wu B, Wang X, Xu C, He B, Cui B, et al. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol 2011; 654(3): 274-9.
70. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza- Hidalgo M, Dillmann W, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 2008; 52(13): 1086-94.
71. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95(26): 15769-74.
72. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999; 96(23): 13496-500.
73. Martin A, Boisgard R, Kassiou M, Dolle F, Tavitian B. Reduced PBR/TSPO expression after minocycline treatment in a rat model of focal cerebral ischemia: A PET study using [(18)F]DPA-714. Mol Imaging Biol 2011; 13(1): 10-5.
74. Neigh GN, Karelina K, Glasper ER, Bowers SL, Zhang N, Popovich PG, et al. Anxiety after cardiac arrest/cardiopulmonary resuscitation: Exacerbated by stress and prevented by minocycline. Stroke 2009; 40(11): 3601-7.
75. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, et al. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res 2008; 1188: 198-206.
76. Peeling J, Yan H, Buist R, Sitar DS, Corbett D. Protective effect of minocycline treatment on striatal ischemia. J Stroke Cerebrovasc Dis 2006; 15(3): 101-5.
77. Lechpammer M, Manning SM, Samonte F, Nelligan J, Sabo E, Talos DM, et al. Minocycline treatment following hypoxic/ ischaemic injury attenuates white matter injury in a rodent model of periventricular leucomalacia. Neuropathol Appl Neurobiol 2008;34(4): 379-93.
78. Chu LS, Fang SH, Zhou Y, Yin YJ, Chen WY, Li JH, et al. Minocycline inhibits 5-lipoxygenase expression and accelerates functional recovery in chronic phase of focal cerebral ischemia in rats. Life Sci 2010; 86(5-6): 170-7.
79. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69(14): 1404-10.
80. Cai ZY, Yan Y, Sun SQ, Zhang J, Huang LG, Yan N, et al. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. Neurosci Bull 2008; 24(5): 305-13.
81. Cai ZY, Yan Y, Chen R. Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull 2010; 26(1): 28-36.
82. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: Improvement by minocycline in vivo and in vitro. Stroke 2006; 37(4): 1087-93.
83. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxicischemic injury. Ann Neurol 2002; 52(1): 54-61.
84. Kremlev SG, Roberts RL, Palmer C. Minocycline modulates chemokine receptors but not interleukin-10 mRNA expression in hypoxic-ischemic neonatal rat brain. J Neurosci Res 2007; 85(11): 2450-9.
85. Tsuji M, Wilson MA, Lange MS, Johnston MV. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol 2004; 189(1): 58-65.
86. Cai Z, Lin S, Fan LW, Pang Y, Rhodes PG. Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience 2006; 137(2): 425-35.
87. Fan LW, Lin S, Pang Y, Rhodes PG, Cai Z. Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat. Eur J Neurosci 2006; 24(2): 341-50.
88. Carty ML, Wixey JA, Colditz PB, Buller KM. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: A comparison of two different dose regimens. Int J Dev Neurosci 2008; 26(5): 477-85.
89. Fox C, Dingman A, Derugin N, Wendland MF, Manabat C, Ji S, et al. Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2005; 25(9): 1138-49.
90. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 2006; 96(3): 706-18.
91. Fan LW, Pang Y, Lin S, Rhodes PG, Cai Z. Minocycline attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neuroscience 2005; 133(1): 159-68.
92. Yang L, Kim JH, Kovacs KD, Arroyo JG, Chen DF. Minocycline inhibition of photoreceptor degeneration. Arch Ophthalmol 2009; 127(11): 1475-80.
93. Theruvath TP, Zhong Z, Pediaditakis P, Ramshesh VK, Currin RT, Tikunov A, et al. Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate storage/reperfusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition. Hepatology 2008; 47(1): 236-46.
94. Dumont EA, Lutgens SP, Reutelingsperger CP, Bos GM, Hofstra L. Minocycline inhibits apoptotic cell death in a murine model of partial flap loss. J Reconstr Microsurg 2010; 26(8): 523-8.
95. Kelly KJ, Sutton TA, Weathered N, Ray N, Caldwell EJ, Plotkin Z, et al. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2004; 287(4): F760-6.
96. Kunugi S, Shimizu A, Kuwahara N, Du X, Takahashi M, Terasaki Y, et al. Inhibition of matrix metalloproteinases reduces ischemiareperfusion acute kidney injury. Lab Invest 2011; 91(2): 170-80.
97. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005; 288(1): F91-7.
98. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54(2): 258-65.
99. Leon H, Baczko I, Sawicki G, Light PE, Schulz R. Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br J Pharmacol 2008; 153(4): 676-83.
100. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122(2): 81-9.
101. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001; 48(6): 1393-9; discussion 9-401.
102. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001; 98(25): 14669-74.
103. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004; 24(9): 2182-90.
104. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004; 101(9): 3071-6.
105. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003; 20(10): 1017-27.
106. Stam-Westerveld EB, Daenen S, Van der Meer JB, Jonkman MF. Eosinophilic cellulitis (Wells' syndrome): Treatment with minocycline. Acta Derm Venereol 1998; 78(2):157.
107. Montemarano AD, Hengge M, Sau P, Welch M. Confluent and reticulated papillomatosis: Response to minocycline. J Am Acad Dermatol 1996; 34(2 Pt 1): 253-6.
108. Davies MG, Piper S. Pyoderma gangrenosum: Successful treatment with minocycline. Clin Exp Dermatol 1981; 6(2): 219-23.
109. Panayi GS, Clark B. Minocycline in the treatment of patients with Reiter's syndrome. Clin Exp Rheumatol, 1989; 7(1): 100-1.
110. Soldato, P. New compounds including drug groups used for treating oxidative stress and/or endothelial disorders of moderate intensity. US7759392 (2010).
111. Del Soldato, P. Nitro or Nitroso derivatives are used in the treatment of oxidative stress and/or endothelial dysfunction, in the treatment of the cardiovascular system hypertension, arteriosclerosis, rheumatoid arthritis, and the gastrointestinal system. US7402600 (2010).
112. Hunter, W.L., Machan, L.S., Larry A.A. Compsn. contg. antiangiogenic factor useful for eliminating biliary obstructions, urethral obstructions, etc. US7820193 (2010).
113. Galibert, L.J., Yan, W. New LDCAM-specific binding agent, useful for treating a disease, e.g. autoimmune, cardiovascular, or pulmonary disease, inflammation, cancer, or infection. EP2133362 (2009).
114. Novartis, A.G. Medicament useful in the treatment of inflammatory, infective or obstructive airways disease e.g. asthma, chronic obstructive pulmonary disease, cystic fibrosis, emphysema, silicosis comprises amine compound; and an antibacterial agent. EP1938822 (2008).
115. Oliner, J.D., Hosung, M. Treating diseases associated with aberrant levels of angiopoietin-2 (Ang-2), such as inflammatory disorders, cancer or retinopathies, comprises administering to a patient an amount of a peptide or peptibody capable of binding Ang-2. EP1764370 (2007).
116. Nelson, M.L., Frechette, R., Viski, P., Ismail, M., Bowser, T., Dumornay, J., Rennie, G., Liu, G., Koza, D., Sheahan, P., Stapleton, K., Hawkins, P., Bhatia, B., Verma, A.K., Mcintyre, L., Warchol, T., Messersmith, D. 9-Substituted minocycline compounds. US6846939 (2005).